22.418 articles found

SYSTEMS AND METHODS FOR ENHANCING OR OPTIMIZING NEURAL STIMULATION THERAPY FOR TREATING SYMPTOMS OF PARKINSON'S DISEASE AND/OR OTHER MOVEMENT DISORDERS

GLINER BRADFORD EVAN.

· 2003-12-10

SYSTEMS AND METHODS FOR ENHANCING OR OPTIMIZING NEURAL STIMULATION THERAPY FOR TREATING SYMPTOMS OF PARKINSON'S DISEASE AND/OR OTHER MOVEMENT DISORDERS

GLINER BRADFORD EVAN.

· 2003-12-10

Use of gaba, inverse agonists in combination with nicotine receptor partial agonist, estrogen, selective estrogen modulators, or vitamin E for the treatment of cognitive disorders

VILLALOBOS ANABELLA.

· 2003-12-02

Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach.

Blandini F.

Exp Neurol · 2003-12-01

DOI: 10.1016/s0014-4886(03)00402-3PMID: 14769348

Neural stem cell therapy in the aging brain: pitfalls and possibilities.

Limke TL, Rao MS.

J Hematother Stem Cell Res · 2003-12-01

DOI: 10.1089/15258160360732641PMID: 14977471

Further experience with extradural motor cortex stimulation for treatment of advanced Parkinson's disease. Report of 3 new cases.

Pagni CA, Zeme S, Zenga F.

J Neurosurg Sci · 2003-12-01

PMID: 14978472

[Pathophysiology and therapy of L-Dopa-induced dyskinesia].

Hadj Tahar A, Bézard E, Grondin R, Gross CE, Bédard PJ.

Rev Neurol (Paris) · 2003-12-01

PMID: 14978413

Treatment of orthostatic hypotension.

Freeman R.

Semin Neurol · 2003-12-01

DOI: 10.1055/s-2004-817727PMID: 15088264

Appropriate dosing of pergolide in monotherapy and adjunctive therapy in Parkinson's disease.

Hattori N.

Curr Opin Neurol · 2003-12-01

DOI: 10.1097/00019052-200312001-00005PMID: 15180134

Rationale for dopamine agonist use as monotherapy in Parkinson's disease.

Schwarz J.

Curr Opin Neurol · 2003-12-01

DOI: 10.1097/00019052-200312001-00006PMID: 15180135

Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease.

Wong KS, Lu CS, Shan DE, Yang CC, Tsoi TH, Mok V.

J Neurol Sci · 2003-12-01

DOI: 10.1016/s0022-510x(03)00217-xPMID: 14607306

[Analysis of direct costs in therapy of Parkinson disease].

Keller S, Kessler T, Meuser T, Fogel W, Bremen D, Jost WH.

Nervenarzt · 2003-12-01

DOI: 10.1007/s00115-003-1582-6PMID: 14647911